These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16300168)

  • 1. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine.
    Dieterle W; Corynen S; Vaidyanathan S; Mann J
    Int J Clin Pharmacol Ther; 2005 Nov; 43(11):527-35. PubMed ID: 16300168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects.
    Ayalasomayajula S; Tchaloyan S; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
    Curr Med Res Opin; 2008 Mar; 24(3):717-26. PubMed ID: 18234150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
    Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
    Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects.
    Vaidyanathan S; Bartlett M; Dieterich HA; Yeh CM; Antunes A; Howard D; Dole WP
    Cardiovasc Ther; 2008; 26(4):238-46. PubMed ID: 19035874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects.
    Limoges D; Dieterich HA; Yeh CM; Vaidyanathan S; Howard D; Dole WP
    Int J Clin Pharmacol Ther; 2008 May; 46(5):252-8. PubMed ID: 18538111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
    Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
    Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
    Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.
    Vaidyanathan S; Camenisch G; Schuetz H; Reynolds C; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
    J Clin Pharmacol; 2008 Nov; 48(11):1323-38. PubMed ID: 18784280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus.
    Zhao C; Vaidyanathan S; Yeh CM; Maboudian M; Armin Dieterich H
    Clin Pharmacokinet; 2006; 45(11):1125-34. PubMed ID: 17048976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren.
    Tapaninen T; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
    J Clin Pharmacol; 2011 Mar; 51(3):359-67. PubMed ID: 20400651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment.
    Vaidyanathan S; Bigler H; Yeh C; Bizot MN; Dieterich HA; Howard D; Dole WP
    Clin Pharmacokinet; 2007; 46(8):661-75. PubMed ID: 17655373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib.
    Prieto-Pérez R; Ochoa D; Cabaleiro T; Román M; Sánchez-Rojas SD; Talegón M; Abad-Santos F
    J Clin Pharmacol; 2013 Dec; 53(12):1261-7. PubMed ID: 23996211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects.
    Vaidyanathan S; Jermany J; Yeh C; Bizot MN; Camisasca R
    Br J Clin Pharmacol; 2006 Dec; 62(6):690-8. PubMed ID: 17118124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin.
    Mück W; Ritter W; Dietrich H; Frey R; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):261-4. PubMed ID: 9208343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects: a randomized, single-blind, parallel-group, placebo-controlled study.
    Hu P; Bartlett M; Karan RS; Jiang J; Zhang S; Zhang J; Howard D; Yeh CM; Al-Fayoumi S; Jarugula V; Dole WP
    Clin Drug Investig; 2010; 30(4):221-8. PubMed ID: 20192280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment.
    Vaidyanathan S; Warren V; Yeh C; Bizot MN; Dieterich HA; Dole WP
    J Clin Pharmacol; 2007 Feb; 47(2):192-200. PubMed ID: 17244770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aliskiren: an oral direct renin inhibitor for the treatment of hypertension.
    Sanoski CA
    Pharmacotherapy; 2009 Feb; 29(2):193-212. PubMed ID: 19170589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of aliskiren/hydrochlorothiazide single-pill combination tablets and free combination of aliskiren and hydrochlorothiazide.
    Yan JH; Jarugula V; Sabo R; Papst CC; Zhang J; Dole WP
    J Clin Pharmacol; 2012 May; 52(5):645-55. PubMed ID: 21659626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers.
    Huang HL; Vaidyanathan S; Yeh CM; Bizot MN; Dieterich HA; Dole WP; Howard D
    Curr Med Res Opin; 2008 Sep; 24(9):2449-56. PubMed ID: 18662494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin.
    Pan HY; Triscari J; DeVault AR; Smith SA; Wang-Iverson D; Swanson BN; Willard DA
    Br J Clin Pharmacol; 1991 Jun; 31(6):665-70. PubMed ID: 1907839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.